209 related articles for article (PubMed ID: 8801057)
1. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.
Black DJ; Kunze KL; Wienkers LC; Gidal BE; Seaton TL; McDonnell ND; Evans JS; Bauwens JE; Trager WF
Drug Metab Dispos; 1996 Apr; 24(4):422-8. PubMed ID: 8801057
[TBL] [Abstract][Full Text] [Related]
2. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.
Kunze KL; Wienkers LC; Thummel KE; Trager WF
Drug Metab Dispos; 1996 Apr; 24(4):414-21. PubMed ID: 8801056
[TBL] [Abstract][Full Text] [Related]
3. Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction.
Kunze KL; Trager WF
Drug Metab Dispos; 1996 Apr; 24(4):429-35. PubMed ID: 8801058
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
[TBL] [Abstract][Full Text] [Related]
5. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.
Neal JM; Kunze KL; Levy RH; O'Reilly RA; Trager WF
Drug Metab Dispos; 2003 Aug; 31(8):1043-8. PubMed ID: 12867493
[TBL] [Abstract][Full Text] [Related]
6. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
[TBL] [Abstract][Full Text] [Related]
7. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
[TBL] [Abstract][Full Text] [Related]
8. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
Thijssen HH; Flinois JP; Beaune PH
Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance.
Takahashi H; Kashima T; Kimura S; Murata N; Takaba T; Iwade K; Abe T; Tainaka H; Yasumori T; Echizen aH
Drug Metab Dispos; 1999 Oct; 27(10):1179-86. PubMed ID: 10497145
[TBL] [Abstract][Full Text] [Related]
11. Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.
Darbyshire JF; Iyer KR; Grogan J; Korzekwa KR; Trager WF
Drug Metab Dispos; 1996 Sep; 24(9):1038-45. PubMed ID: 8886617
[TBL] [Abstract][Full Text] [Related]
12. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M; Backman JT; Neuvonen M; Laitila J; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2001 Apr; 69(4):194-200. PubMed ID: 11309547
[TBL] [Abstract][Full Text] [Related]
13. Possible interaction between warfarin and fluconazole.
Gericke KR
Pharmacotherapy; 1993; 13(5):508-9. PubMed ID: 8247921
[TBL] [Abstract][Full Text] [Related]
14. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
[TBL] [Abstract][Full Text] [Related]
15. Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin.
Kunze KL; Eddy AC; Gibaldi M; Trager WF
Chirality; 1991; 3(1):24-9. PubMed ID: 2039681
[TBL] [Abstract][Full Text] [Related]
16. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.
Thijssen HH; Drittij MJ; Vervoort LM; de Vries-Hanje JC
Clin Pharmacol Ther; 2001 Sep; 70(3):292-8. PubMed ID: 11557918
[TBL] [Abstract][Full Text] [Related]
17. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.
Rettie AE; Korzekwa KR; Kunze KL; Lawrence RF; Eddy AC; Aoyama T; Gelboin HV; Gonzalez FJ; Trager WF
Chem Res Toxicol; 1992; 5(1):54-9. PubMed ID: 1581537
[TBL] [Abstract][Full Text] [Related]
18. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments.
Komatsu K; Ito K; Nakajima Y; Kanamitsu Si; Imaoka S; Funae Y; Green CE; Tyson CA; Shimada N; Sugiyama Y
Drug Metab Dispos; 2000 Apr; 28(4):475-81. PubMed ID: 10725317
[TBL] [Abstract][Full Text] [Related]
19. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes.
Yamazaki H; Shaw PM; Guengerich FP; Shimada T
Chem Res Toxicol; 1998 Jun; 11(6):659-65. PubMed ID: 9625734
[TBL] [Abstract][Full Text] [Related]
20. Effect of rutin on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats.
Chan E; Hegde A; Chen X
J Pharm Pharmacol; 2009 Apr; 61(4):451-8. PubMed ID: 19298691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
